Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Avidity Biosciences
Biotech
Novartis pays $12B for late-stage dystrophy biotech Avidity
Almost a year after buying Kate Therapeutics, Novartis scooped up another San Diego-based dystrophy biotech in one of the biggest deals of 2025.
James Waldron
Oct 26, 2025 4:01pm
Avidity's latest DMD data drop assuages safety concerns: analyst
Mar 17, 2025 2:00pm
Analysts dig into Avidity's DMD win, revealing nuances in data
Aug 12, 2024 9:24am
Avidity therapy shows possible benefit in muscular dystrophy
Jun 12, 2024 7:00am
BMS, Avidity add another $100M to cardiovascular partnership
Nov 28, 2023 6:30am
Avidity says FDA has 'eased' partial hold on lead asset
May 17, 2023 11:16am
